Rwanda Launches Marburg Virus Vaccine Trial Amid Outbreak

The East African nation begins vaccinating healthcare workers and at-risk individuals as the virus claims 12 lives.

Rwanda has started a vaccine trial to combat the Marburg virus outbreak, focusing on healthcare workers and those in contact with confirmed cases.
The outbreak, declared on September 27, has resulted in 12 deaths and 46 confirmed cases, with 29 individuals currently in isolation.
The Sabin Vaccine Institute has provided 700 doses for the trial, which is being conducted in partnership with the Rwanda Biomedical Centre.
Strict measures, including suspension of school and hospital visits, have been implemented to curb the spread of the virus.
Marburg virus, similar to Ebola, is transmitted through close contact with bodily fluids and has a high fatality rate of up to 88% without treatment.